Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 4/20 | 0.52 |
| ▸ | FYN | P06241 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 10/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618984 | 0.84 | TTK (0.48) | FLT3FYNKDRTTKADORA3 | |
| SCHEMBL5408800 | 0.84 | FLT3 (0.54) | FLT3FYNTTK | |
| SCHEMBL14573302 | 0.82 | KDR (0.49) | FYNKDRTTK | |
| SCHEMBL14573299 | 0.82 | FLT3 (0.54) | FLT3TTKADORA3 | |
| SCHEMBL5403960 | 0.79 | FLT3 (0.56) | FLT3FYNTTK | |
| SCHEMBL5411618 | 0.79 | FLT3 (0.56) | FLT3TTKADORA3 | |
| SCHEMBL5401420 | 0.79 | FLT3 (0.56) | FLT3TTK | |
| SCHEMBL5404865 | 0.79 | FLT3 (0.56) | FLT3KDRTTK | |
| SCHEMBL5618795 | 0.79 | KDR (0.46) | FYNKDRTTK | |
| SCHEMBL5400806 | 0.78 | FLT3 (0.48) | FLT3FYNTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | claimed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | claimed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | MAP3K8, MAP3K2, MAP3K5 | FLT3 216/4885FYN 528/4885KDR 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.